Meinhard Schmidt, Non-Executive Chairman of Oncimmune, commented: “Adam’s direct experience of developing and executing global growth strategies within healthcare will be hugely beneficial to Oncimmune as we continue to expand into additional markets with additional products. On behalf of the Board, I would like to take this opportunity to welcome Adam to the Company. We believe he will make a make a significant contribution to further enhancing and delivering on Oncimmune’s strategy.”
Oncimmune Holdings plc (LON:ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announced the appointment of Dr Adam Hill MB PhD, to the Company’s Board as Chief Medical Officer and Chief Strategy Officer, commencing on 9 April 2018.
Adam is a dual-qualified Clinician and Engineer, with a career built in industry, academia and practising medicine. During his career, Adam has held Chief Medical Officer and other senior management roles at private and listed companies, supplemented by advisory and government policy appointments.
Most recently, Adam was Chief Medical Officer and later Chief Strategy Officer of McLaren Applied Technologies, where he focused on applying the company’s deep technical expertise to improving health outcomes. Adam developed a Digital Therapeutics strategy and grew a team of experienced professionals across Commercial, Product, Programme, Quality and Technical disciplines to deliver against it. Previously, he was Chief Medical Officer at Sectra AB, the listed medical technology and encryption communications company, and a Management Consultant with PA Consulting.
Commenting on his appointment, Adam Hill said: “Oncimmune’s core technology has enormous potential based on its ability to detect cancer four years earlier than other methods using a robust blood test – a liquid biopsy. I look forward to bringing my experience to the Company and working with the team to fully develop this potential as we commercialise the platform globally.”
Adam graduated from Imperial College London as a Medical Doctor, whilst also earning a PhD in Engineering, attending Imperial College Business School, and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers. Adam has built a portfolio of over 100 academic peer-reviewed, policy and popular-media publications. Currently, he is both a Visiting Professor in Global Health Innovation at Imperial College London, and sits on the Advisory Board of Imperial College Health Partners.
